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Calmodulin (CaM) is aCa2bindingproteinmodulatingmul-
tiple targets, several of which are associated with cardiac patho-
physiology. Recently, CaM mutations were linked to heart
arrhythmia. CaM is crucial for cell growth and viability, yet the
effect of the arrhythmogenic CaMmutations on cell viability, as
well as heart rhythm, remains unknown, and only a few targets
with relevance for heart physiology have been analyzed for their
response to mutant CaM.We show that the arrhythmia-associ-
ated CaMmutants support growth and viability of DT40 cells in
the absence of WT CaM except for the long QT syndrome
mutant CaM D129G. Of the six CaM mutants tested (N53I,
F89L, D95V, N97S, D129G, and F141L), three showed a
decreased activation of Ca2/CaM-dependent kinase II, most
prominently the D129G CaM mutation, which was incapable
of stimulating Thr286 autophosphorylation. Furthermore, the
CaM D129G mutation led to bradycardia in zebrafish and an
arrhythmic phenotype in a subset of the analyzed zebrafish.
Ca2 is the main trigger for muscle contraction (reviewed in
Refs. 1 and 2). Ca2 signaling is highly regulated in cardiomyo-
cytes and controls a number of important proteins governing
release and uptake of Ca2 into the sarcoplasmic reticulum
(SR),3 as well as cardiomyocyte contraction. Impaired contract-
ibility and lethal cardiac arrhythmias may result from dysregu-
lated Ca2 signaling and cycling. One of the main players in
Ca2-mediated effects is calmodulin (CaM), a ubiquitous intra-
cellular Ca2 receptor involved in a vast number of physiolog-
ical processes including cell proliferation and muscle activity
(reviewed in Ref. 3). Identical CaM proteins are expressed in
humans from three independent genes located on different
chromosomes (4). It is well known that malfunctioning of sev-
eral CaM-regulated proteins may cause heart failure including,
among many others, the cardiac Ca2release channel (RyR2)
and the L-type Ca2 channel (reviewed in Ref. 2). In addition,
CaM-regulated protein kinases, in particular the Ca2/CaM-
dependent kinase II (CaMKII), have been found to be dysregu-
lated in diverse cardiac disorders (reviewed in Refs. 5–8).
CaM plays a critical role in catecholaminergic polymorphic
ventricular tachycardia (CPVT), as well as in long QT syn-
drome (LQTS) (9, 10). Nyegaard et al. (9) identified a mutation
in theCaMgene 1 locus on chromosome14 of a Swedish family,
segregating with a dominantly inherited form of CPVT. This
mutation changes residue 53 in theCaMprotein from an aspar-
agine to an isoleucine. In addition, a de novomutation in CaM
gene 1 changing residue 97 from asparagine to serinewas found
by screening CPVT patients. Thus, it was concluded that the
CaM genes may be candidates for genetic screening of patients
with tachycardia. Using whole exome sequencing of patients
with LQTS, Crotti et al. (10) found three other de novo muta-
tions (D130G, which was represented in two patients, and
D96V and F142L; (these mutations are numbered D129G,
D95V, and F141L, respectively, in this work in line with the
nomenclature used in the first article describing arrhythmo-
genic CaMmutations) (9)) in the CaM genes 1 and 2. An addi-
tional inherited CaM 1 mutation F90L (referred to as F89L in
thiswork)was discovered in a familywith a history of idiopathic
ventricular fibrillation (11). Five novel CaM mutations in the
CaM gene 2 have been found in three patients with LQTS
(N97S, N97I, and D133H) and two with both LQTS and CPVT
features (D131E and Q135P) (12). Two arrhythmogenic CaM
mutations, D129G associated with LQTS (13) and A102V asso-
ciated with CPVT (14), were found in the CaM 3 gene. A recent
investigation on the whole exome of 38 elusive LQTS patients
revealed five CaM positive cases, of which one had a novel
mutation (E140G) (15). In addition, two novel mutations
(D131V andD131H), both associatedwith LQTS,were recently
identified (16). Fig. 1 summarizes the currently available infor-
mation on mutated CaM amino acids associated with arrhyth-
mia. The CPVT mutations exhibit either moderately higher
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(N53I) or slightly reduced (N97S andA102V) Ca2 affinities (9,
14), whereas the CaM mutations in LQTS patients all have a
high impact on the CaMCa2 affinity, likely because of disrup-
tion of EF hand 3 or 4 Ca2 binding (10) (Fig. 1).
A number of cardiac target proteins are regulated byCaM. So
far, the effect of CaMmutants on the interactionwith andmod-
ulation of the RyR2 and the cardiac L-type channel have been
investigated in some detail (17, 18). FRET studies with cardiac
SR membranes indicated that CPVT CaM mutants increase
binding to the RyR2, enhance its channel opening probability,
and lead to spontaneousCa2waves and spark activity, features
not seen for LQTS-causing CaM mutants (17). A study using
guinea pig ventricular myocytes showed that LQTS mutants
induce increased action-potential prolongation, increase Ca2
transient amplitudes, and suppress the CaM-dependent inacti-
vation of the of L-type channel Cav1.2 (18).
Little is known about the effect of CaMmutants on the func-
tion of CaMKII, an important player in cardiac Ca2 signaling.
CaMKII regulates the RyR2, Cav1.2, and Nav1.5 in a strictly
Ca2/CaM-dependent manner (reviewed in Ref. 19). Ca2/
CaM activates CaMKII by displacing the autoinhibitory
domain of the CaMKII allowing transphosphorylation on posi-
tionThr286, which renders the enzyme active (20). Thr286 phos-
phorylation increases the affinity of CaM to the enzyme 1,000-
fold, keeping it active even at lowCa2 concentrations during a
certain time period, which allows the enzyme to act as a chem-
ical memory of previous heartbeats by integrating individual
Ca2 signals (21). Increased activity of CaMKII is implicated
in several heart diseases including dilated cardiomyopathy,
cardiac hypertrophy, and arrhythmia, mainly because of an
increased leak of Ca2 from the SR and Ca2-mediated
arrhythmias (5, 22).
In this study, our aim was to examine the effect of six CaM
mutants (N53I, F89L, D95V, N97S, D129G, and F141L) in an in
vitro system with conditional CaM expression in DT40 cells
(23). In addition, the goal was to investigate whether the CaM
mutants are able to activate CaMKII and to analyze how the
mutant with themost pronounced effect in vitro (CaMD129G)
affects the heart rhythm of zebrafish. Our study shows that the
arrhythmogenic CaM mutants affect the examined functions
differentially and indicates that the mutation changing the first
Ca2 coordinating residue fromAsp toGly in EFhand 4 ofCaM
affects the in vitro parameters to the highest degree and causes
an arrhythmogenic phenotype in vivo.
Results
The CaM D129G Mutant Cannot Rescue DT40 Cells De-
pleted of WT CaM—We have previously established a cellu-
lar CaM knock-out/knock-in system with conditional CaM
expression (tet off system) (Fig. 2A) (23). This is a unique cellu-
lar model system because it allows expressing CaM variants in
the absence of endogenous CaM in a vertebrate cell line after
4–5 days of tetracyclin treatment (Fig. 2B). This enabled us to
study the effect of CaM mutations on basic cellular processes
such as cell growth, viability, and cell cycle regulation, as well as
regulation of CaM-dependent signaling pathways and interac-
tion of CaM with its numerous target proteins. In the present
study we used this system to investigate the known cardiac fail-
ure causing CaM mutants for their potential to support cell
growth. Stable expression of the different mutants in a WT
CaMbackground did not affect growth, whereas removingWT
CaM in the absence of ectopically expressed CaM blocked cell
growth and viability completely. HA tagged CaMwas fully able
to restore these features as reported before (23). Remarkably,
among the tested CaM mutations, the D129G mutant
decreased cell growth and viability to a large degree, whereas
among the othermutations only CaMF89L orN97S showed an
effect on these parameters, however to a much lesser degree as
compared with CaM D129G (Fig. 2, C and D). Because none of
the mutant proteins were expressed to a higher extent as com-
FIGURE 1.Representation of pathogenic CaMvariants associatedwith CPVT, LQTS, or iodiopathic ventricular fibrillation (IVF). The backbone is shown
in gray except for themutated residues where the side chains in stick representation have been included and color-coded either blue or red (red indicates the
residue is directly involved in Ca2 coordination). Ca2 is shown in yellow space fill presentation. Text boxes show the amino acid conversion, as well as the
arrhythmia associated with the mutation and in which of the three calmodulin genes (CALM) the mutation has been identified and references to the discov-
eries. The CaMmodel is based on the 1.7 Å structure of Ca2 bound WT CaM (Protein Data Bank code 1CLL) modified from Ref. 48.
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pared with the wild type and most of them still were able to
support cell growth to a major degree (Fig. 2B), we assume that
the observed effects were not the result of different levels of
mutated CaM. In addition, earlier work (24) showed that low-
ering CaM concentrations down to 40% does not alter growth
properties of DT40 cells. To exclude the possibility that the lack
of viability was a clonal artifact, multiple independent D129G-
expressing clones were tested (data not shown). The viability
did not reflect the clonal diversity in HA-CaM expression
because different cell lines with various CaM expression levels
gave similar results.
CaMKII Activity Is Affected by CaMMutations to a Various
Degree, Most Prominently with CaMD129G—CaMKII plays a
central role in a large number of Ca2/CaM-signaling pathways
FIGURE 2. The CaMmutant D129G is not able to replaceWT CaM in DT40 cells. The CaM1 gene of the chicken DT40 cells was silenced by disrupting exon
3 (red) by insertion of a tetracyclin-regulatable rat CaM cDNA (green) and the other allele by insertion of a selection marker (23). In this cell line, both alleles of
the CaM 2 gene had previously been disrupted (24) rendering the tetracyclin-regulatable rCaM (TetReg-CaM) as the only CaM expressed. Stable transfection
ofHA-taggedversionsofCaM (blue) followedbydown-regulationof rCaMenables exchangeofWT forHA-taggedWTandmutantCaM.B,Westernblot analysis
of 25g of total protein/lane fromDT40 clones showing levels of TetReg-CaM andHA-tagged CaMnon-treated (control, upper panel incubatedwith anti-CaM
antibody) and 4 days of tet treatment showing almost complete exchange ofWT formutated HA-tagged CaM (lower panel incubatedwith both anti-CaM and
anti-HA antibodies). Because the CaM antibody has different affinities for the mutant versions of CaM, the signals shown for HA-CaM do not represent the
precise amounts of these proteins. C and D, growth curves of cells expressing HA-tagged CaM WT and mutants grown in the absence (C) or presence (D) of
tetracyclin (tet). Error bars are S.E. from five independent repetitions. E, bar diagram showing% viable cells at 120-h tet treatment for all clones comparedwith
the control without tet. Error bars are S.E. from five independent repetitions.
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and is essential for cardiomyocyte functions (25). We therefore
asked whether the arrhythmia-causing CaM mutants were
capable of activating CaMKII. To do this we used the CaMKII
sensor Camui (26), which is based on theCaMKII isoform and
has been shown to mimic the heart tissue predominant -iso-
form of CaMKII (27). Camui exploits the structural and func-
tional features of CaMKII by containing a fused fluorescent
protein on theNandC termini of CaMKIIwithin Förster radius
in the inactive state. CaMKII activation leads to separation
of the fluorophores and thereby unquenching of the donor
mCerulean (CFP). Adding WT CaM increased CFP fluores-
cence, as did the N53I, N97S, and F141L mutants, whereas the
maximal fluorescence as compared with WT CaM was
strongly decreased for the F89L and D95V and most promi-
nently for the D129G, as well as for the Ca2-binding deficient
mutants (Fig. 3A). The strongly reduced ability of D129G to
activate CaMKII was similar to that of the Ca2-binding defi-
cientmutants (EF12, EF34, and EF1234 (numbers indicate inac-
tivated Ca2 binding sites)) (Fig. 3A). In cardiomyocytes the
mutant CaMs are expected to exert their effects by competing
with WT CaM because only one allele of the three genes
expressing CaM is changed (reviewed in Ref. 28). Tomimic this
situation for CaM D129G, which in all our assays yielded the
strongest effect, wemixed CaMD129G andWTCaM in differ-
ent ratios andmeasured Camui activation following addition of
Ca2 (Fig. 3B). Exchanging WT for D129G CaM reduced the
Camui activation as compared with only reducing WT CaM
with buffer (dilution effect), indicating a dominant negative
effect of the D129G (Fig. 3B). The CaM mutant with both EF
hands 3 and 4 mutated had an even more severe dominant
negative effect (Fig. 3B). Because the speed of Ca2 fluxes in the
sarcoplasm regulates the dynamics of the Ca2 receptor CaM
and its interactions with targets and thereby the heart rhythm,
we investigated whether the CaM D129G mutant would affect
CaMKII in an initial activation phase. Kinetic measurements
comparing the activation speed of CaMKII activation in the
presence of WT CaM or CaM D129G alone or mixed in a 2:1
ratio showed that CaMKII activation by CaM was significantly
reduced when CaM D129G was present (Fig. 3C). These com-
bined data show that the D129GCaMmutant can exert a dom-
inant negative effect on the CaMKII function in vitro.
CaM D129G Cannot Stimulate Phosphorylation of CaMKII
Thr286 and Phosphorylation of Downstream Targets Is Mark-
edly Reduced—A small yet consistent Camui activation change
by CaMD129G in our in vitro experiment indicated some con-
tribution of the mutant in the activation. To investigate the
phosphorylation status of CaMKII in the presence of WT or
D129G CaM, we purified ectopically expressed rat CaMKII
from HEK cells. CaMKII is well known to become activated by
Ca2/CaM through binding and steric removal of a regulatory
domain leading to autophosphorylation of Thr286 (29). Incuba-
tion of recombinant CaMKII with D129G CaM led to a dimin-
ished autophosphorylation of CaMKII Thr286, as compared
with incubation with WT CaM (Fig. 4, A and B). To test
whether D129G CaM affected the CaMKII-dependent phos-
phorylation of downstream targets, we analyzed the in vitro
phosphorylation of the CaMKII substrate autocamtide-2
(KKALRRQETVDAL) and found that in the presence ofD129G
CaM phosphorylation of the peptide was significantly reduced
as compared with WT CaM (Fig. 4C). These results along with
the Camui data indicate that D129G is able to bind to CaMKII
but cannot cause its activation.
CaM D129G Expression in Zebra Fish Causes Decreased
Heart Rate—To examine whether wild type CaM and CaM
D129Gwould elicit different effects on the development and/or
FIGURE 3. CaM D129G activates CaMKII only to a minor degree and
decreases WT CaM-mediated activation. A, recombinant heart disease-re-
lated CaMs with the indicated amino acids mutated or WT CaM were incu-
bated with HeLa cell lysate containing the Camui CaMKII sensor, and peak
unquenching of mCerulean was measured in the presence of 2.5 M [Ca2].
CaMwithdisruptedCa2binding at EFhands 1 and2 (EF12), 3 and4 (EF34), or
1–4 (EF1234) were used as negative controls. B, bar diagram shows the effect
of CFP emission on adding 1 M WT CaM, CaM 129, or EF34 alone (left-hand
side), or mixing WT CaM with the mutant CaM proteins (right-hand side). To
test different ratios of WT:mutCaM, the mutCaM was added to give a final
total CaMconcentration (WTmutCaM) of 1M. Addition of buffer served as
a control for the effect of reducingWT CaM. C, activation kinetics of CaMKII in
the presence of D129G CaM. p 0.05 as calculated by paired two-tailed anal-
ysis. Error bars represent S.E. from three independent experiments.
CPVT and LQTS CalmodulinMutations
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function of the embryonic heart, we injected eitherWTCaMor
CaM D129G synthetic RNA into myl7:GFP embryos. In myl7:
GFP transgenic zebrafish embryos, GFP expression is driven
by the cardiac-specific promoter myl7 (30), allowing in vivo
phenotypic analysis and quantitative measurement of cardiac
parameters (31). As shown in Fig. 5A,WTorD129GCaMover-
expression did not affect the overall development of zebrafish
embryos or the morphogenesis of the hearts. After 2 days of
development, well patterned hearts capable of propelling circu-
lation through the body were observed in uninjected controls
and D129G or WT CaM RNA-injected embryos (Fig. 5A).
Although CaM-WT RNA-injected embryos had a heart rate
similar to that observed in uninjected control embryos, D129G
overexpression reduced the heart rate to 83% of the level
observed in controls This is a moderate difference, however
statistically significant (n 128, p 0.001) (Fig. 5B) consider-
ing that endogenous CaM is present as well. Interestingly,8%
of D129G RNA-injected embryos exhibited an abnormal car-
diac rhythm where the atrium beats twice per ventricular con-
traction (Fig. 5, C and D). Overall, these results demonstrate a
significant impact of D129G on the heart rate and conduction
of the developing heart in zebrafish.
Discussion
In this study we tested the arrhythmogenic CaM mutations
N53I, F89L, D95V, N97S, D129G, and F141L in a cell-based
system and in a CaMKII activation assay. We found that the
CaM mutant D129G stands out from six investigated cardiac
arrhythmia-related CaMmutations in interfering with the via-
bility of a genetically modified vertebrate cell line expressing
exclusively mutant CaM. Further, CaM D129G showed the
strongest effect on CaMKII activity measured in a FRET-based
assay and also diminished CaMKII substrate phosphorylation
as compared with WT CaM. Based on these results we tested
the D129G mutant in vivo. Expression of CaM D129G in
zebrafish led to decreased heart rate and in a subpopulation of
animals to a 2:1 ratio of atrium to ventricle heart rate denoted as
breakdance phenotype.
CaM is themajor sensor of Ca2 signals in all eukaryotic cells
regulating a multitude of physiological processes including
muscle contraction. In cardiac tissue CaM is involved in the
tuning of ion channels including the SR Ca2 release channel
RyR2, potassium, and sodium channels in the sarcolemma
directly involved in excitation-contraction coupling (reviewed
in Refs. 28 and 32). Several of these ion channels are further
FIGURE 4. Lack of CaMKII Thr286 phosphorylation in the presence of CaM D129G and reduced phosphorylation of a downstream target peptide.
Purified CaMKII was stimulated with either WT CaM or D129G CaM under various [Ca2]. A, representative Western blot analysis of phosphorylation analyzed
with an anti-Thr(P)286/287 specific antibody. Ctr indicates control without added Ca2. B, quantification of Western blot analysis showing Thr(P)286 CamKII to
total CaMKII ratios relative to non-Ca2-stimulated control from three independent experiments. Error bars represents S.D. C, quantitativemass spectrometry
analysis of the autocamtide 2 target tryptic peptide (QET(phosp)VDAL, highlighted in blue) following recombinant CaMKII stimulation with either WT or
D129G CaM. Measurements were performed in triplicate at 2.5 and 15 min after the reaction was initiated. *, p 0.05; **, p 0.005 calculated using either
homoscedastic or heteroscedastic two-tailed t test, depending on the statistical value of the F-test (heteroscedastic if p 0.05). Proteins with t test p values
smaller than 0.05were considered as significantly alteredbetween the two tested conditions. The values are given as fold changeof theD129G versusWTCaM.
Detected CaMKII tryptic Thr286 phosphopeptide is shown for comparison.
CPVT and LQTS CalmodulinMutations
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regulated indirectly through Ca2/CaMmodulation of cytoso-
lic enzymes such as CaMKII and calcineurin. In addition, CaM
regulates transcriptional processes important for proper heart
function.One example is the phosphorylation of class II histone
deacetylases by the CaM/CaMKII pathway. In the phosphory-
lated stage these deacetylases are excluded from the nucleus
and incapable of repressing genes that are involved in heart
hypertrophy (reviewed in Ref. 5). CaM and CaMKII were also
shown to affect the heart rhythm by regulating the expression
of ion channels involved in excitation contraction coupling
(reviewed in Refs. 33 and 34). The recent finding that CaM
mutations in one of three expressed CaM genes, which all
encode the same protein, may cause several types of heart
arrhythmias, mainly CPVT and LQTS, came as a surprise as
CaM is perfectly conserved in vertebrates underlining the
importance of maintenance of an unchanged primary struc-
ture. Even though several laboratories have initiated work to
investigate the molecular basis of how CaM mutation cause
heart arrhythmia, little is known about the molecular mecha-
nisms affected by CaMmutations in the heart.
We replaced WT CaM with six arrhythmia-causing CaM
mutants and found that only CaM D129G affected cell growth
and viability to a major degree. This indicated that exchanging
aspartic acid at position 129 with glycine renders CaM incapa-
ble of supporting basic vertebrate cell functions. One would
therefore expect that such amutation would not be compatible
with life. However, it has to be considered that three genes code
for an identical CaM protein in mammals and that the D129G
mutationwas only found in one allele of all the threeCaMgenes
(10, 13, 15). All three CaM genes are transcribed in the heart as
measured by quantitative PCR (10). Highest mRNA levels were
found for the CaM 3 gene followed by the CaM 2 and the CaM
1 gene in the human left ventricle. However, it is not known
how much each transcript contributes to the expression of
FIGURE5. ImpactofCaMD129Gontheheart rateandconductionof thedevelopingheart in zebrafish.A, representative imagesof zebrafish injectedwith
RNAcoding for eitherWTCaMor themutantD129G, aswell as non-injected control (upper panel). The lower panel showsGFPexpression in the zebrafishhearts.
B, bar diagram showing relative heartbeat normalized to non-injected control embryos. Heartbeat measurements were based on fluorescent intensities from
cardiac contractions in non-injected control embryos, WT CaM-injected embryos, and D129G-injected embryos. D129G-injected embryos exhibit a heart rate
of 83%comparedwith non-injected control andCaM-WT-injected embryos. ***, p 0.001.C, contractions in the atriumand ventricle of a non-injected animal.
D, a representative trace from aD129G-injected embryo exhibiting a 2:1 atrium to ventricle beat ratio, observed in8%of D129G-injected embryos (n 128).
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CaM on the protein level. In addition, it is possible that the
different transcripts are used for translation in different subcel-
lular locations in cardiomyocytes in analogy to findings in neu-
rons (35). Therefore, it seems that this mutation can be toler-
ated for normal human development but would affect heart
physiology by a dominant effect overWTCaM. Asp129 is a very
important residue because it coordinates Ca2 in the fourth EF
hand Ca2 binding loop. All other LQTS-related mutations
investigated in this report, even though directly at Ca2 coor-
dinating positions, showed considerablymilder effects on Ca2
affinity (10). Changing an aspartate to a glycine at position 129
may have severe structural consequences because glycine
allows the highest flexibility. This is corroborated by an earlier
study where we showed that changing Asp129 to Ala did not
abolish cell growth and viability (23). In addition, NMR data of
CaM D129G from a study by Crotti et al. (10) support the
notion that a local structural change along with reduced Ca2
binding may explain the effect of this mutant in the functions
analyzed in our study.
We tested the CaM mutants for their capability to bind and
stimulate CaMKII autophosphorylation using the Camui FRET
system (36). CaMKII functions in the heart by regulating a
number of Ca2, K, and Na channels through phosphoryla-
tion. Its chronic activation may cause heart failure through a
variety of mechanisms (5, 32). One crucial target relevant for
heart rhythm control and phosphorylated by CaMKII is the
RyR2. Phosphorylation of theRyR2 enhancesCa2 release from
the SR disturbing normal Ca2 cycling (reviewed in Ref. 5). In
the heart, the major CaMKII isoform is CaMKII, which is
mainly found in the sarcoplasm and acts in regulation of ion
channels and Ca2 handling, whereas CaMKII is found pre-
dominantly in the nucleus and regulates hypertrophic gene
activity (5). As in other CaMKII isoforms, the active form of
CaMKII is stabilized by phosphorylation on Thr286 as well as
other post-translational modifications such as oxidation and
O-linked glycosylation rendering the enzyme Ca2/CaM-inde-
pendent (27). Recent investigations indicate that Thr286 phos-
phorylation is necessary but not sufficient for full CaMKII acti-
vation. Coultrap et al. (37) found that higher than 15–25%
activation of CaMKII by preincubation with Ca2/CaM is an
exception and needs a special type of binding by the substrate.
Full activation toward regular substrates such as tyrosine
hydroxylase andGluR1 requires additional regulation by Ca2/
CaM. Thus, incomplete and substrate-dependent autonomy
prevents uncoupling from subsequent regulation. The same
group later showed that further stimulation of partially auton-
omous CaMKII is physiologically important because autono-
mous CaMKII must be further stimulated by Ca2/CaM to
enhance synaptic strength (38). Molecular mechanisms of this
additional Ca2/CaM-dependent activation of partially auton-
omous CaMKII have not been established so far.
Hwang et al. (17) tested the available CaMmutants for their
potential to affect the RyR2 calcium release channel. Because
CaMKII is known to phosphorylate and activate theRyR2 chan-
nel, the arrhythmia-causing CaMmutants were also compared
with theWT for their potential to regulate CaMKII and thereby
have an effect on RyR2 activity. Neither of the mutants led to a
decreased CaMKII activity as comparedwith theWT (17). This
is in contrast to our results carried out with the same CaMKII
sensor used by Hwang et al. (17). Not only did we see a strong
decrease in CaMKII activity with theD129G, but also theD95V
and N97S gave significantly reduced (23 and 63%, respectively)
CaMKII peak activity (Fig. 3A). Earlier literature indicates that
EF hands 3 and 4 in CaM are of crucial importance for CaMKII
activation (39), and as position Asp129 is the first Ca2 coordi-
nating residue in EF loop 4, our results are not surprising. Based
on these data, it is surprising that Hwang et al. (17) did not find
a difference between mutants affecting EF hands 3 and 4 and
WTCaM in CaMKII activation. Crotti et al. (10) found that the
C-domain of CaM D129G had a 54-fold lower Ca2 affinity
(kd 150M) as comparedwith the intactWTCaMC-domain,
whichwouldmake it unlikely thatCaMD129Gwould be able to
fully activate CaMKII at lowCa2concentration. In thework by
Hwang et al. (17), ATPwas not added in the CaMKII activation
assay. It is therefore questionable whether the CaMKII sensor
was autophosphorylated. Our experiments show that the addi-
tion of CaM D129G causes a small decrease in Camui FRET
indicative of CaMbinding; however, binding only occurs under
saturating Ca2 conditions and does not involve Thr286 phos-
phorylation. From this, we hypothesize that CaM D129G can
bind but not stimulate CaMKII autophosphorylation. This
leads to a competitive binding responsible for the dominant
negative delay in the activation profile of CaMKII (Figs. 3C and
6). The pleiotropic nature of CaMKII, targeting both func-
tion and expression of proarrhythmic as well as anti-arrhyth-
mic molecules (reviewed in Ref. 40), makes it difficult to derive
a conclusionontheconsequencesof theD129GCaMdefectat the
organismal level. It is, however, safe to conclude that the autono-
mous activation of CaMKII is affected. Studies into molecular
mechanismof howCaMmutations affect CaMKII and in particu-
lar how they can exhibit a dominant negative effect on CaMKII
should be done on a structural level in the future.
Based on results obtained in vitro, we then askedwhether the
D129G CaM, which exhibited the most prominent effect in
vitro would also have an effect in vivo. D129G CaM RNA-
injected in zebrafish embryos exhibited a major effect on
zebrafish heart physiology. Expressing CaM D129G in
zebrafish eggs not only altered the heart rhythm but also led to
the “breakdance” phenotype characterized by an atrium to ven-
tricle beating ratio of 2:1 of 2-day-old zebrafish. This indicates
for the first time that thismutant affects the heart function in an
in vivo vertebrate model system. The D129G-induced 2:1 beat
phenotype resembles LQTS. This phenotype is comparable
with the human long QT syndrome, an arrhythmia caused by a
modification of ion channels involved in cardiac repolarization
(41). The low penetrance (only 8% of the investigated animals
show this phenotype) is likely to be the result of the labile nature
of injected RNA. Clearly, generating stable transgenic fish or
knock-in D129G fish would help clarify the possible causative
relationship between D129G and LQTS. Because it is known
that CaM regulates K cannels involved in repolarizing current
bymoving K ions outward (42) andmutations in zebrafish K
channels induce the bradycardia/LQTphenotype (43), it is pos-
sible that the observed phenotypes are correlatedwith failure in
Ca2/CaMregulation of K channels either directly or through
CaMKII.
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Experimental Procedures
DNA Constructs
In this study, six different heart arrhythmia-linked CaM
mutations, CaM N53I, CaM F89L, CaM D95V, CaM N97S,
CaM F129L, and CaM F141L, were analyzed. The numbers
indicate the position of amino acid exchange without the initial
methionine. Site-directed mutagenesis was performed in the
pCMV_HA-CaM_WT_Eco vector, described in Ref. 23.
For protein expression CaM N53I, CaM F89L, CaM D95V,
CaMN97S, CaMF129L, andCaMF141Lmutations weremade
by the quick changemethod in a pGemex vector. For DT40 cell
expression, the pCMV-HAEco vector providing a short protein
tag, earlier shownnot to interferewith the function of CaM (23)
was used. Mutant Camui constructs were made by PCR tech-
niques in the Camui vector containing full-length CaMKII
kindly provided by Yasunori Hayashi (36).
Cell Lines
DT40-derived clone ET 1–50 (23) grown in RPMI with 10%
FBS and 1% chicken serum served as the parental cell line for
generating clones expressing HA-tagged mutant CaMs. Trans-
fection of 5,000,000 cells was performed with 15 g of linear-
ized pCMV-HA CaM Eco-gpt in 100 l of electroporation
buffer (20mMHEPES, 135mmol/literKCl, 2mmol/literMgCl2,
0.5% Ficoll 400, 200 mmol/liter ATP, and GSH 500mmol/liter,
adjusted to pH 7.4 with KOH). Electroporation was done with
the Bio-Rad gene pulser system in 1-mm cuvettes at 124 V and
750 microfarad. Immediately afterward, 500 l of spent
medium was added. After 2 min of incubation, the cells were
transferred to 2 ml of spent medium. Transfected cells were
transferred to a 96-well plate in selection medium prepared by
adding the following to the growth medium: 250 mg/liter xan-
thine, 20mg/liter hypoxanthine, and 15mg/liter mycophenolic
acid prepared according to the manufacturer’s recommenda-
tions (Sigma-Aldrich). After 6 days, colonies were transferred
to fresh selection medium, and clones were expanded for 3–7
days before freeze stockswere prepared. The cloneswere tested
by Western blot analysis with mouse HA and mouse CaM
antibody to confirmHA-CaMexpression. The specificity of the
used antibodieswas verified by probing cells that donot contain
native CaM or the HA epitope (23).
Growth Curve and Viability Assay
DT40 cell growth wasmonitored for 7 days with andwithout
tetracycline treatment. The cells were adjusted to 50,000–
75,000 cells/ml. Counting and FACS analysis was performed
every day. Every second day, the cells were reseeded at 50,000–
75,000 cells/ml. Cells pellets were tested by Western blot anal-
ysis for the expression of CaM and HA-CaM.
Western Blot Analyses
DT40 cell pellets were lysed in 50 mmol/liter Tris-HCl, pH
7.5, 150 mmol/liter NaCl, 0.5% Nonidet P-40, 2 mmol/liter
EDTA, 1 mmol/liter DTT, and protease inhibitor mixture for
20 min on ice followed by centrifugation at 15,000  g for 10
min at 4 °C. Proteins in lysates were separated by SDS-PAGE
(12%polyacrylamide)After blotting, themembranewas treated
for 10 min in 0.02% glutaraldehyde. The blot was incubated
with the primary antibodymouse CaM (Millipore, catalog no.
05-173) 1:8,000 or mouse HA11 (Covance, catalog no.16B12)
FIGURE 6. Hypothetical model for CaMKII activation delay. Half of the dodecameric holoenzyme has been sketched with the green units representing the
regulatory domain and the blue units the hub domain. CaM is in yellow (WT) or orange (D129G), and the red dots represent phosphorylation sites Thr286. The
presence of CaMD129Gwill lead to binding without Thr286 phosphorylation. Because the D129Gwill occupy a CaM binding site, phosphorylation (drawing 1)
and full holoenzyme activation (drawing 2) will be delayed (Fig. 3C).
CPVT and LQTS CalmodulinMutations
DECEMBER 23, 2016•VOLUME 291•NUMBER 52 JOURNAL OF BIOLOGICAL CHEMISTRY 26643
 at D
EF Consortium
 - U
niv Library of Southern D
enm
ark on January 24, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
1:1,000. For development the Amersham Biosciences ECL
PrimeWestern blotting detection reagent was used, and the blots
were analyzedwith Bio-RadChemieDocMP. A prestained broad
range marker (Thermo Fisher Scientific, catalog no. 26619) was
used to verify the size of the observed bands.
Zebrafish
Zebrafish Husbandry and Transgenic Lines—Zebrafish of
transgenic line, myl7:GFP were maintained and bred as
described previously (44). Full-length D129G and WT CaM
cDNAwas cloned into pCS2 3XFLAG. FormRNA synthesis,
plasmids were linearized by NotI andmRNA synthesized using
the SP6 mMESSAGE mMachine kit according to the manufa-
cturer’s manual (Ambion).
Zebrafish Injections—100 pg of CaM mutant and WT CaM
mRNA were injected into one-cell stage embryos col-
lected from crosses of myl7:GFP zebrafish. Embryos were
then maintained for further phenotypic analysis at 2 days
postfertilization.
Zebrafish Cardiac Imaging and Analysis—Movies of GFP-
labeled Tg(myl7:GFP) hearts were taken at 30 frames/s under a
Zeiss Stemi SV11 microscope. A custom-designed area scan
algorithm calculated pixel density in a user-specified area on
the heart, and the value was quantified as a unit of fluorescence
intensity over time in frames (30 frames/s). This generated a
trace of cardiac contractions, and the data were plotted as car-
diac trace over time (s).
CaM Expression and Purification
pGemex-2-CaM constructs were transformed into Esche-
richia coli competent cells BL-21 (DE3). The cells were incu-
bated at 37 °C until the A600 was 0.8–1, and CaM expression
was induced with 100 mol/liter isopropyl -D-thiogalactopy-
ranoside. CaMwas detected in culture medium after overnight
incubation. Culture medium with additional 5 mmol/liter
CaCl2 was applied to pre-equilibrated HiTrap Phenyl Sephar-
ose column (GE Healthcare), and CaM elution proceeded
according to Ref. 45. All purified CaM proteins used in the
Camui/CaMKII experiments were dialyzed overnight against a
buffer containing 50mmol/liter Tris-HCl, pH 8, and 0.1mmol/
liter EGTA using 10,000 molecular weight cutoff SnakeSkin
dialysis tubing (Thermo Fisher Scientific).
Camui in Vitro Assay
The Camui mYpet-CaMKII-mCerulean construct, kindly
provided by Yasunori Hayashi (36), or derived mutants gener-
ated in our laboratory were transfected into HeLa cells using
Lipofectamine (Invitrogen). HeLa cells grown under standard
conditions (DMEM, 10% FBS, 1% penicillin/streptomycin)
were seeded at 8,400,000 cells in a T175 flask the day before
transfection and harvested 2 days after transfection. Cell lysis
was done in 2 ml of buffer (40 mmol/liter HEPES NaOH, pH 8,
5 mmol/liter magnesium acetate, 0.1 mmol/liter EGTA, 0.01%
Tween, 1mmol/liter DTT, and protease inhibitor mixture) and
followed by Dounce homogenization. Lysates were cleared by
10 min of centrifugation at 10,000  g at 4 °C, and aliquots of
the supernatantwere shock frozen in liquid nitrogen and stored
at 80 °C. CFP fluorescence was measured at 37 °C using a
Tecan infinite F200 Pro (Thermo Fisher Scientific) and the
ex448/em485 filter setting. For activation of Camui, 1 mol/liter
CaM (unless otherwise indicated) and 40 mol/liter ATP were
used. CaCl2was added to reach the indicated freeCa2 concen-
trations as calculated by the Max chelator program (46). Back-
ground readings were deducted from all measurements to
exclude contribution from lysate components.
Camui Kinetics Measurements
The velocity of the CaM/Camui-CaMKII reaction was calcu-
lated using amodified setup of theCamui in vitro assay. CFP fluo-
rescence emitted from Camui containing HeLa cell lysate in a
96-well platewith1MCaMand40MATP(final concentrations
after stimulation) wasmeasured every1 s. After10 s, an auto-
mated injector addedCaCl2 to reach anestimated final concentra-
tionof200MfreeCa2.Thebackgroundmeasurements (prior to
addition of calcium)were deducted, and velocity of theCFP emis-
sion increase was calculated as V  [(Max  B)/2]/t, where V is
velocity,Max is theCFP emission (average of 10measurements at
the reaction saturation level), B is the background (average of 9
measurements in the absence of Ca2), and t is the time (s). A
logarithmic regression model equation (y  *ln(x) ) calcu-
lated inMicrosoftOffice Excel was used to calculate the time (t) at
the half-maximum ((Max	)/2) of the CFP emission.
CaMKII Expression and Purification
His-tagged CaMKII was produced in HEK 293F cells by
transfection of constructs using polyethylenimine (Sigma). The
cells were grown in DMEM supplemented with 10% FBS (Bio-
chrom AG), 1% penicillin/streptomycin for 3 days after trans-
fection, when cells were harvested by centrifugation at 1,000
g for 4 min at 4 °C, washed once in PBS, and then lysed in a
buffer containing 0.3% Nonidet P-40, 0.5 M NaCl, 20 mM
Na3PO4, 30 mM imidazole, and complete protease inhibitor
mixture (Roche). FollowingDounce homogenization, the lysate
was cleared by centrifugation for 30 min at 20,000  g. The
supernatant was incubated overnight with nickel-Sepharose
(GE Healthcare) and washed with two volumes of lysis buffer
before elution using buffer containing 500mM imidazole to give
a semipurified His-CaMKII solution of unknown CaMKII con-
centration. The HeLa and HEK 293F cell lines were exclusively
used for protein production and tested periodically for myco-
plasma infection and phenotypic characteristics.
CaMKII in Vitro Activation
11 l of semipure His-CaMKII was mixed with 1 M wild
type or mutated CaM, 40 M ATP and desired concentrations
of Ca2 to give a final volume of 12.5 l and incubated at 37 °C
for 30min. Proteins in the reactionmix were separated by SDS-
PAGE (10% polyacrylamide) and analyzed by Western blot
using antibodies against Thr(P)286 CaMKII (Abcam, catalog no.
ab32678) and CaMKII (Sigma-Aldrich, catalog no. C6974).
Western blots were visualized and analyzed using the Chemi-
Doc MP bioimaging system (Bio-Rad).
Mass Spectrometry
All chemicals were purchased from Sigma-Aldrich, unless
otherwise stated. TiO2 beads were from GL Sciences Inc.
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(Tokyo, Japan). Endopeptidase Lys-C was from Wako.
Sequence grade trypsin was from Promega (Madison, WI).
Recombinant human histidine-tagged CaMKII was obtained
from Life Technologies. Autocamtide-2 was from Santa Cruz
Biotechnology Inc. Okadaic acid was purchased from MP Bio-
medicals (Thermo Fisher Scientific). Empore C18 extraction
disk was from 3M Bioanalytical Technologies (St. Paul, MN).
Poros Oligo R3 reversed phase chromatographic material was
from PerSeptive Biosystems (Framingham, MA). Reprosil-C18
3-m beads were purchased from MikroLab Aarhus S/A
(Højbjerg, Denmark). All reagents used in the experiments
were of sequencing grade. All solutions were made with ultra-
pure water (ELGA Purelab Ultra water system).
Stimulation of CaMKII Autophosphorylation
Protein concentration was determined by amino acid com-
position analysis using a Biochrom30 amino acid analyzer (Bio-
chrom, Cambridge, UK). Autophosphorylation of CaMKII
was induced by adding 1.5 g of CaMKII to a reaction mix
containing 50mMTris-HCl, pH 7.5, 100 mMNaCl, 0.1% BSA, 1
mM CaCl2, 10 mMMgCl2, 100 M ATP, 1 M okadaic acid, and
10 g of wild type CaM or D129G CaM mutant, respectively,
with the addition of 30 g of substrate peptides (Autocam-
tide-2; KKALRRQETVDAL). Stimulation of CaMKIIwas per-
formed for 2.5 and 15 min at 37 °C in a final volume of 54.8 l.
The reaction was stopped by adding reducing agent (10 mM
DTT) and endopeptidase Lys-C to the mix, followed by 1 h of
incubation at room temperature. Each stimulation condition
was performed in triplicate. Peptide digestion was performed
by using either Lys-C alone or Lys-C in combination with tryp-
sin. Lys-C only was used for peptides, which would have been
too short if digested with trypsin. Lys-C generated peptides
were alkylated in 20 mM iodoacetamide for 30 min at room
temperature in the dark. Subsequently, the samples were
digested with trypsin at an enzyme to substrate ratio of 1:50
for 12 h at 37 °C. The samples were acidified to 5% formic acid
and desalted using Poros R3 RP column packed in a P200 stage
tip with C18 3M plug. The purified peptide samples were dried
by lyophilization and labeled using isobaric tagging labeling
(iTRAQTM 4-plex; Applied Biosystems, Foster City, CA) as
described by the manufacturer. After labeling, all samples were
pooled into one tube and dried by vacuum centrifugation to
50 l for phosphopeptide enrichment by TiO2. The TiO2
enrichment of phosphopeptides was performed essentially as
previously described (47). Prior to nanoLC-MS/MS analysis,
the phosphorylated peptide samples were resuspended in 0.1%
TFA and desalted using Poros R3 RP column packed in a P200
stage tip with C18 3M plug. Purified phosphopeptide samples
were dried by lyophilization and stored at80 °C until further
analysis.
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